Markets

Acne biotech Foamix Pharmaceuticals files for a $75 million IPO

An image of a pen and a calculator
Credit: Shutterstock photo

Foamix Pharmaceuticals, an Israeli biotech developing topical foam treatments for moderate-to-severe acne, filed on Wednesday with the SEC to raise up to $75 million in an initial public offering. The company expects to enter Phase 3 trials for its lead candidate, a 4% minocycline foam formulation, in 2015.

The Weizmann Science Park, Israel-based company, which was founded in 2003 and booked $3 million in licensing agreements for the 12 months ended June 30, 2014, plans to list on the NASDAQ under the symbol FOMX. Foamix initially filed confidentially on May 20, 2014. Barclays and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More